Goldman Sachs raised the firm’s price target on Amicus (FOLD) to $11 from $9 and keeps a Neutral rating on the shares. Amicus reported Q3 revenue in line with estimates, and Goldman Sachs is encouraged by continued commercial execution per positive GAAP net income in Q3, which should be sustained from here, and management’s confidence in achieving FY25 consensus revenue, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Therapeutics Reports Strong Q3 2025 Results
- Amicus Therapeutics Reports Strong Q3 Earnings Growth
- Amicus’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Analyst
- Amicus Therapeutics: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
- Amicus reports Q3 non-GAAP EPS 17c, consensus 12c